Literature DB >> 8726591

The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension.

H Jick1, L E Derby, V Gurewich, C Vasilakis.   

Abstract

We conducted a case-control study based on computer-recorded information accrued in the United Kingdom General Practice Research Database to assess and compare the relation between different antihypertensive drug therapies and myocardial infarction in patients with no known clinical or laboratory risk factors for myocardial infarction other than hypertension. Cases were treated hypertensive patients with no other known risk factors who developed a first acute myocardial infarction between January 1, 1993, and October 31, 1994. They were ascertained from a review of the clinical record together with a questionnaire filled out by the attending general practitioner. Controls were matched to each case for age, sex, general practice, and index date. Antihypertensive therapy was derived from the computerized patient record. The study consisted of 210 cases and 793 controls. Compared with users of beta-blockers alone, the adjusted relative risk (RR) estimates for all other treatment regimens were close to 1.0. A comparison of users of calcium channel blockers alone with users of beta-blockers alone yielded a RR estimate of 0.9 (95% CI 0.5, 1.7). We conclude that the risk of acute myocardial infarction in otherwise healthy, treated hypertensive patients is not materially associated with the particular drug they receive.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726591

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  11 in total

1.  Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction.

Authors:  C R Meier; R G Schlienger; H Jick
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

2.  1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart?

Authors:  F H Leenen
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 3.  The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?

Authors:  M C Ruddy
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 4.  Meta-analyses of antihypertensive therapy: Are some of them misleading?

Authors:  E Grossman; U Goldbourt
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

5.  No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease.

Authors:  Mark T Osterman; Yu-Xiao Yang; Colleen Brensinger; Kimberly A Forde; Gary R Lichtenstein; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2011-07-13       Impact factor: 11.382

6.  Constituent country inequalities in myocardial infarction incidence and case fatality in men and women in the United Kingdom, 1996-2005.

Authors:  A R Davies; E Grundy; D Nitsch; L Smeeth
Journal:  J Public Health (Oxf)       Date:  2010-07-15       Impact factor: 2.341

7.  Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction.

Authors:  Raymond G Schlienger; Hershel Jick; Christoph R Meier
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

8.  Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova; John Robson; Margaret May; Peter Brindle
Journal:  BMJ       Date:  2007-07-05

9.  General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction.

Authors:  L J Tata; J West; C Smith; P Farrington; T Card; L Smeeth; R Hubbard
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

10.  Risk of myocardial infarction and overall mortality in survivors of venous thromboembolism.

Authors:  Consuelo Huerta; Saga Johansson; Mari-Ann Wallander; Luis A García Rodríguez
Journal:  Thromb J       Date:  2008-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.